Medicare Part B Drug Reimbursement Bill Misses Real Issue On Sequester – Rep. Waxman
This article was originally published in The Pink Sheet Daily
Executive Summary
At a House Energy & Commerce Health Subcommittee hearing June 28, Waxman expressed skepticism about legislation directing CMS to suspend cuts to Part B drug payments under the federal budget sequester.
You may also be interested in...
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.